

Status: Currently Official on 15-Feb-2025
Official Date: Official Prior to 2013
Document Type: USP Monographs
DocId: GUID-A028892B-70C8-4CE7-B3F5-DAF21D15D8D7_1_en-US
DOI: https://doi.org/10.31003/USPNF_M33182_01_01
DOI Ref: 4e1y1

© 2025 USPC
Do not distribute

Finasteride Tablets

» Finasteride Tablets contain not less than 95.0 percent and not more than 105.0 percent of finasteride ($C_{23}H_{36}N_2O_2$).

Packaging and storage—Preserve in tight, light-resistant containers, and store at controlled room temperature.

USP REFERENCE STANDARDS (11)—

[USP Finasteride RS](#)

Identification—The retention time of the major peak in the chromatogram of the Assay *preparation* corresponds to that in the chromatogram of the *Standard preparation*, as obtained in the Assay.

DISSOLUTION (711)—

Medium: water; 900 mL.

Apparatus 2: 50 rpm.

FOR PRODUCTS LABELED AS 5-MG TABLETS—

Time: 45 minutes.

Determine the amount of $C_{23}H_{36}N_2O_2$ dissolved by employing the following method.

Mobile phase—Prepare a filtered and degassed mixture of acetonitrile and water (29:21). Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

Diluting solution—Prepare a solution of acetonitrile and water (7:3).

Standard solution—Dissolve an accurately weighed quantity of [USP Finasteride RS](#) in *Diluting solution*, and dilute quantitatively, and stepwise if necessary, with *Diluting solution* to obtain a solution having a known concentration approximately equivalent to the sample under test.

Chromatographic system (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a 220-nm detector and a 4.6-mm × 5-cm column that contains packing L1. The column temperature is maintained at 45°. The flow rate is about 2 mL per minute. Chromatograph the *Standard solution*, and record the peak responses as directed for *Procedure*: the capacity factor, k' , is not less than 2.0; the column efficiency is greater than 1000 theoretical plates; the tailing factor is less than 2; and the relative standard deviation for replicate injections is less than 2.0%.

Procedure—Separately inject equal volumes (about 200 µL) of the solution under test and the *Standard solution* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity of $C_{23}H_{36}N_2O_2$ dissolved.

Tolerances—Not less than 75% (Q) of the labeled amount of $C_{23}H_{36}N_2O_2$ is dissolved in 45 minutes.

FOR PRODUCTS LABELED AS 1-MG TABLETS—

Time: 30 minutes.

Mobile phase—Prepare a degassed mixture of acetonitrile and water (11:9). Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

Diluting solution—Prepare a solution of water and acetonitrile (7:3).

Standard solution—Dissolve an accurately weighed quantity of [USP Finasteride RS](#) in *Diluting solution*, to obtain a solution having a known concentration of 0.1 mg per mL. Dilute this solution quantitatively, and stepwise if necessary, in 0.5% sodium lauryl sulfate to obtain a solution containing 0.001 mg of finasteride per mL.

Chromatographic system (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a 220-nm detector and a 4.6-mm × 15-cm column that contains 5-µm packing L11. The column temperature is maintained at 45°. The flow rate is about 1.5 mL per minute.

Chromatograph the *Standard solution*, and record the peak responses as directed for *Procedure*: the column efficiency is not less than 5000 theoretical plates; the tailing factor is not more than 2; and the relative standard deviation for replicate injections is not more than 2%.

Procedure—Separately inject equal volumes (about 100 µL) of the solution under test and the *Standard solution* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity of finasteride ($C_{23}H_{36}N_2O_2$) dissolved.

Tolerances—Not less than 80% (Q) of the labeled amount of $C_{23}H_{36}N_2O_2$ is dissolved in 30 minutes.

UNIFORMITY OF DOSAGE UNITS (905): meet the requirements.

Assay—

Mobile phase—Prepare a filtered and degassed mixture of 2.5 mM phosphoric acid and acetonitrile (1:1). Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

Diluting solution—Prepare a solution of acetonitrile and water (7:3).

Standard preparation—Dissolve an accurately weighed quantity of [USP Finasteride RS](#) in *Diluting solution*, and dilute quantitatively, and stepwise if necessary, with *Diluting solution* to obtain a solution having a known concentration of about 100 µg per mL.

Assay preparation—Weigh and finely powder not fewer than 20 Tablets. Transfer an amount of powder equivalent to about 10 mg of finasteride, accurately weighed, to a 100-mL volumetric flask, dissolve in and dilute with *Diluting solution* to volume, and mix.

Chromatographic system (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a 240-nm detector and a 4.6-mm × 10.0-cm column that contains packing L1. The column temperature is maintained at 45°. The flow rate is about 1.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the capacity factor, k' , is not less than 2.0; the column efficiency is not less than 1000 theoretical plates; the tailing factor is not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%.

Procedure—Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of finasteride ($C_{23}H_{36}N_2O_2$) in the portion of Tablets taken by the formula:

$$100C(r_U/r_S)$$

in which C is the concentration, in mg per mL, of [USP Finasteride RS](#) in the *Standard preparation*; and r_U and r_S are the peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
FINASTERIDE TABLETS	Documentary Standards Support	SM52020 Small Molecules 5

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 32(6)

Current DocID: GUID-A028892B-70C8-4CE7-B3F5-DAF21D15D8D7_1_en-US

DOI: https://doi.org/10.31003/USPNF_M33182_01_01

DOI ref: [4e1y1](#)